<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34924158</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2530-0180</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Endocrinologia, diabetes y nutricion</Title><ISOAbbreviation>Endocrinol Diabetes Nutr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Effect of the type of specialized nutrition support on the course of the patient with amyotrophic lateral sclerosis (ALS). Interhospital registry SCLEDyN.</ArticleTitle><Pagination><StartPage>699</StartPage><EndPage>707</EndPage><MedlinePgn>699-707</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.endien.2021.11.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2530-0180(21)00158-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease in which specialized nutritional support is essential. The objectives of our study were to describe nutritional support at the beginning of follow-up and its impact on anthropometry and survival.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An interhospital registry was created for the hospitals of Castilla-Le&#xf3;n through a web platform designed for this purpose. An anamnesis was carried out on the evolution and nutritional history of the disease; and classical anthropometry was determined. The prescribed nutritional treatment was recorded. The parameters were measured at the beginning, at six and twelve months of nutritional follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 93 patients [49 (52.7%) spinal; 44 (47.3%) bulbar)] were analyzed. The nutritional support route at the beginning was oral diet in 36 (38.7%) patients; oral nutritional supplementation (SON) in 46 (49.5%) patients; and in 11 (11.8%) patients percutaneous endoscopic gastrostomy (PEG). A decrease in the body mass index (BMI) was observed between the first and second visit [Start: 24.18 (3.29) kg/m<sup>2</sup>; 6 months: 23.69 (4.12) kg/m<sup>2</sup>; P&#x202f;&lt;&#x202f;.05]. Less weight loss was observed at 6 months compared to the start of nutritional follow-up [Start: 8.09 (8.72)%; 6 months: 1.4 (6.29)%; P&#x202f;&lt;&#x202f;.01]. 36 (38.7%) patients died but with no differences according to when nutritional support was started. Survival from the onset of symptoms was higher in the group of patients with artificial nutrition, although without reaching statistical significance [Oral: 28 (20.25) months; SON: 30 (16.75-48.25) months; PEG: 39 (27-52) months; P&#x202f;=&#x202f;.90].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with ALS present a severe deterioration in nutritional status before the start of nutritional support. After the nutritional intervention, a slowdown in weight loss and nutritional deterioration was observed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 SEEN and SED. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf3;pez-G&#xf3;mez</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain; Instituto de Investigaci&#xf3;n en Endocrinolog&#xed;a y Nutrici&#xf3;n (IENVA), Universidad de Valladolid, Valladolid, Spain. Electronic address: jjlopez161282@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballesteros-Pomar</LastName><ForeName>Mar&#xed;a D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Complejo Asistencial Universitario de Le&#xf3;n, Le&#xf3;n, Spain; Instituto de Investigaci&#xf3;n en Endocrinolog&#xed;a y Nutrici&#xf3;n (IENVA), Universidad de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Hoyos</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain; Instituto de Investigaci&#xf3;n en Endocrinolog&#xed;a y Nutrici&#xf3;n (IENVA), Universidad de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pintor de la Maza</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Complejo Asistencial Universitario de Le&#xf3;n, Le&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penacho-L&#xe1;zaro</LastName><ForeName>M &#xc1;ngeles</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Hospital de El Bierzo, Le&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palacio-Mures</LastName><ForeName>Jose Mar&#xed;a</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hospital Universitario Rio Hortega, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abreu-Pad&#xed;n</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Complejo Asistencial de Segovia, Segovia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz Gallego</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Complejo Asistencial de &#xc1;vila, &#xc1;vila, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Luis-Rom&#xe1;n</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Spain; Instituto de Investigaci&#xf3;n en Endocrinolog&#xed;a y Nutrici&#xf3;n (IENVA), Universidad de Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Endocrinol Diabetes Nutr (Engl Ed)</MedlineTA><NlmUniqueID>101717565</NlmUniqueID><ISSNLinking>2530-0180</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005774" MajorTopicYN="N">Gastrostomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018529" MajorTopicYN="N">Nutritional Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Esclerosis lateral amiotr&#xf3;fica</Keyword><Keyword MajorTopicYN="N">Gastrostom&#xed;a endosc&#xf3;pica percut&#xe1;nea</Keyword><Keyword MajorTopicYN="N">Nutritional support</Keyword><Keyword MajorTopicYN="N">Oral nutritional supplementation</Keyword><Keyword MajorTopicYN="N">Percutaneous endoscopic gastrostomy</Keyword><Keyword MajorTopicYN="N">Soporte nutricional</Keyword><Keyword MajorTopicYN="N">Suplementaci&#xf3;n oral nutricional</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>20</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34924158</ArticleId><ArticleId IdType="doi">10.1016/j.endien.2021.11.032</ArticleId><ArticleId IdType="pii">S2530-0180(21)00158-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>